(Q37144877)

English

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

scientific article published on 28 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

multicenter clinical trial

0 references

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

international scale

1 reference

based on heuristic

inferred from title

author name string

Yoshinori Shinohara

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Naoto Takahashi

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kaichi Nishiwaki

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Masayuki Hino

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Makoto Kashimura

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hisashi Wakita

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yoshiaki Hatano

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Akira Hirasawa

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yasuaki Nakagawa

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kuniaki Itoh

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hidekazu Masuoka

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Nobuyuki Aotsuka

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yasuhiro Matsuura

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sinobu Takahara

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Koji Sano

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jun Kuroki

16

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Tomoko Hata

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hirohisa Nakamae

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Atsuko Mugitani

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Takahiko Nakane

20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yasushi Miyazaki

21

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Takenori Niioka

22

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Masatomo Miura

23

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kenichi Sawada

24

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

28 May 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

98

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1407-1413

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

6 September 2017

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

14 September 2017

Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

27 June 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

27 June 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3762097

3 September 2018

Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2013.085167

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37144877&oldid=2235857745"